Androgen Replacement Therapy, Risks and Benefits

  • C. Wang
  • R. S. Swerdloff
Part of the Mineralogical Society Series book series (ENDO, volume 5)


The primary goal of androgen replacement therapy is to develop and maintain male sexual characteristics and sexual function, as well as to preserve anabolic effects on nonreproductive organs such as maintenance of muscle and bone mass (Bhasin et al, 1995; Wang and Swerdloff, 1997; Nieschlag and Behre, 1990,1998). Testosterone (T) formulations are predominantly used for androgen replacement therapy for hypogonadal men. Occasionally, supraphysiological (pharmacological) doses of androgen are administered for their anabolic effects. The use of androgens in the absence of medical indications (androgen abuse) for sports and body building purposes are discussed in Chapter 11.


Androgen Receptor Testosterone Replacement Testosterone Replacement Therapy Androgen Deficiency Testosterone Enanthate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, Heines M. Androgen-behavior correlations in hypogonadal men and eugonadal men: II. Cognitive behavior. Hormones and Behavior 1998; 33:85–94.PubMedCrossRefGoogle Scholar
  2. Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 1992; 75:1503–1507.PubMedCrossRefGoogle Scholar
  3. Archer J. The influence of testosterone on human aggression. Br J Psychol 1991 82:1–28.PubMedGoogle Scholar
  4. Arias IM. The effects of anabolic steroids on liver function. In: Gross F, ed. Protein Metabolism. Berlin: Springer-Verlag, 1962:434–445.Google Scholar
  5. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994; 79:561–567.PubMedCrossRefGoogle Scholar
  6. Behre HM, Klienh S, Leifke E, Link TM, Nieschlag E. Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386–2390.PubMedCrossRefGoogle Scholar
  7. Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992:75:1204–1210.PubMedCrossRefGoogle Scholar
  8. Besa EC. Hematologic effects of androgens revisited: an alternative therapy in various hematologic conditions. Serum Hematol 1994; 31:138–145.Google Scholar
  9. Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C. Pharmacology, Biology and Clinical Application of Androgens. Wiley-Les, New York, 1996.Google Scholar
  10. Bhasin S, Storer tW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1–7.PubMedCrossRefGoogle Scholar
  11. Bhasin S, Storer TW, Berman N, Yarasheski K, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407–13.PubMedCrossRefGoogle Scholar
  12. Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, Pandian MR, Goldberg R, Berman N. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992; 74:75–83.PubMedCrossRefGoogle Scholar
  13. Brodoky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469–3485.CrossRefGoogle Scholar
  14. Bulter GE, Sellar RE, Walker RF, Hendry M, Kelnar CI, Wu fC. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 1992; 75:37–44.CrossRefGoogle Scholar
  15. Burris AS, Banks SM, Carter CS, Davidson TM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. JAndrol 1992; 13:297–304.Google Scholar
  16. Cantrill JA, Davis P. Laya DM, Newman M, Anderson DC. Which testosterone replacement therapy? Clin Endocrinol (Oxf) 1984; 21:97–107.Google Scholar
  17. Christiansen K, Knussman R. Androgen levels and components of aggressive behavior in men. HormBehav 1987a; 21:170–180.Google Scholar
  18. Christiansen K, Knussman R. Sex hormones and cognitive functioning in men. Neurospychobiology 1987b; 18:27–36.Google Scholar
  19. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989; 261:2525–2530.PubMedCrossRefGoogle Scholar
  20. Dabs JM. Testosterone, aggression and delinquency. In Bhasin S, Gabelnick H, Spieler J, Swerdloff RS, Wang C (eds). Pharmacology, Biology and Clinical Aapplication of Androgens. Wiley-Liss: New York 1995; pp 179–189.Google Scholar
  21. Davis SR, Burger HG. Use of androgens in postmenopausal women. Curr Opin Obstet Gynecol 1997; 9:177–180.PubMedGoogle Scholar
  22. De Lignieres B. Transdermal dihydrotestosterone treatment of ‘andropause’. Ann Med 1993; 25:235–241.PubMedGoogle Scholar
  23. De Lorimier AA, Gordon GS, Lower RC, Carbone JV. Methyltestosterone, related steroids, and liver function. Arch Int Med 1965; 116:289–294.Google Scholar
  24. Dobs AS, Hoover DR, Chen MC, Allen R. Pharmacokinetic characteristics, efficacy and safety of buccal testosterone in hypogonadal males: a pilot study. J clin Endocrinol Metab 1998; 83:33–39.PubMedCrossRefGoogle Scholar
  25. Edwards JP, Zhi L, Poolay CL, Tagley CM, West SJ, Wang MW, Gottarchis MM, Pathirama C, Shrader WT, Jones TK. Preparation, resolution, and biological evaluation of 5-aryl-l, 2-dihydro-5H-chromeno [3,4-f]quinolines:potent, orally active, nonsteroidal progesterone receptor agonists. J Med Chem 1998; 41:2779–2785.PubMedCrossRefGoogle Scholar
  26. Findlay JC, Place VA, Snyder PJ. Transdermal delivery of testosterone. J Clin Endocrinol Metab 1987; 64:266–268.PubMedCrossRefGoogle Scholar
  27. Finkelstein J. Androgens and osteoporosis. Clinical Aspects. In Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C (eds) Pharmacology, Biology and Clinical Application of Androgens. Wiley-Less, New York, 1995; pp 265–277.Google Scholar
  28. Finkelstein JW, Susman EJ, Chinchilli WM, Kunselman SJ, D’Arcangelo MR, Schwab J, Demers JM, Liben LS, Lookingbill G, Kulin AE. Estrogen or testosterone increases self-reported aggressive behaviors in hypogonadal adolescents. J Clin Endocrinol Metab 1997; 82:2433–2438.PubMedCrossRefGoogle Scholar
  29. Friedl KE, Hannan CJJ, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39:69–74.PubMedCrossRefGoogle Scholar
  30. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15:212–215.PubMedGoogle Scholar
  31. Gooren LJ. Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav 1987; 16:463–473.PubMedCrossRefGoogle Scholar
  32. Gould DJ, Canliffe WJ, Smiddy EG. Anabolic steroids in hereditary angioedema. Lancet 1978; 1:770–771.PubMedCrossRefGoogle Scholar
  33. Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. In Williams Textbook of Endocrinology, Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds), W B Saunders; Philadelphia, 1998, pp 819-873.Google Scholar
  34. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A. Effects of androgen administration in men with AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129:18–26.PubMedGoogle Scholar
  35. Hamann LG, Higuchi RI, Zhi L, Edwards JP, Wang XN, Marschke KB, Kong JW, Farmer LJ, Jones TK. Syntheses and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono [5,6-g] quinolines. J Med Chem 1998; 41:623–639.PubMedCrossRefGoogle Scholar
  36. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990; 71:216–222.PubMedGoogle Scholar
  37. Janowsky JS. Oviatt SK, Orwell KS. Testosterone influences spatial cognition in older men. Neurosc 1994; 108:325–332.Google Scholar
  38. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. 1996; 81:4358–4365.Google Scholar
  39. Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991; 146:1566–1570.PubMedGoogle Scholar
  40. Kumar N, Didolkar AK, Monder C, Bardin DW, Sundaram K. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992; 130:3677–3683.PubMedCrossRefGoogle Scholar
  41. Marin P, Lonn L, Andersson B, Oden B, Olbe L, Bengtsson B, Bjorntorp P. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissue in vivo in men: effect of testosterone. J Clin Endocrinol Metab 1996; 81:1018–1022.PubMedCrossRefGoogle Scholar
  42. Matsumoto AM, Sanblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, Bermner WJ. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives and sleep. Clin Endocrinol 1985; 22:713–721.Google Scholar
  43. McDonnell DP, Norris JD. Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone. Osteopros Int 1997; 7:S29–S34.CrossRefGoogle Scholar
  44. Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and the metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74:623–628.PubMedCrossRefGoogle Scholar
  45. Morishima A, Grumback MM, Simpson ER, Fisher C, Qui K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689–3698.PubMedCrossRefGoogle Scholar
  46. Muurahainen N, Mulligan K. Clinical trials update in human immunodeficiency virus wasting. Semin Oncol 1998; 25:104–111.PubMedGoogle Scholar
  47. Nieschlag E, Behre HM (eds). Testosterone: Action, Deficiency, Substitution. Berlin: Springer-Verlag, 1990 (1st edition), 1998 (2nd edition).Google Scholar
  48. Nieschlag E, Mauss J, coert A, Kicovic PM. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh) 1975; 79:366–374.Google Scholar
  49. O’Carroll R, Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf) 1985; 23:527–538.Google Scholar
  50. Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS. Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate—a clinical research center study. J Clin Endocrinol Metab 1995; 80:3567–3575.PubMedCrossRefGoogle Scholar
  51. Sands R, Studd J. Exogenous androgens in postmenopausal women. Am J Med 1995; 98:76S–79S.PubMedCrossRefGoogle Scholar
  52. Scaramelli JJ, Brown WA. Serum testosterone and agressiveness in hockey players. Psychosom Med 1978; 40:262–265.Google Scholar
  53. Schaison G, Nahonl K, Couzinet B. Percutaneous dihydrotestosterone (DHT) treatment. In Nieschlag E, Behre HM (eds). Testosterone: action deficiency, substitution. Berlin: Springer Verlag, 1990; pp 155–164.Google Scholar
  54. Sheffer AL, Fearon DT, Austen KF. Methyl testosterone therapy in hereditary angioedema. Ann Int Med 1997; 86:306–308.Google Scholar
  55. Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil Womens Med 1998; 43:98–103.PubMedGoogle Scholar
  56. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056–1061.PubMedCrossRefGoogle Scholar
  57. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51:1335–1339.PubMedCrossRefGoogle Scholar
  58. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37:425–430.PubMedGoogle Scholar
  59. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1987; 69:523–527.CrossRefGoogle Scholar
  60. Sweeney EC, Evans DJ. Hepatic lesions in patients treated with synthetic anabolic steroids. J Clin Path 1976; 29:626–633.PubMedGoogle Scholar
  61. Wang C and Swerdloff RS. Androgen replacement therapy. Ann Med 1997; 29:365–370.PubMedGoogle Scholar
  62. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996a; 81:3654–3662.PubMedCrossRefGoogle Scholar
  63. Wang C, Alexander G, Berman N, Salahian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996b; 81:3578–3583.PubMedCrossRefGoogle Scholar
  64. Wang C, Iranmanesh A, Berman N, McDonald V, Steiner B, Ziel F, Paulkner SM, Dudley RC, Veldhuis D, Swerdloff RS. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men. A clinical Research Center Study. J Clin Endocrinol 1998; 83:2749–2757.CrossRefGoogle Scholar
  65. Wang C. Androgen delivery systems: overview of existing methods and application. In Pharmacology, Biology and Clinical Applications of Androgens. Bhasin S, Gabelnick HL, Spieler JM, Swerdloff rs, wang C. Wiley-Liss, New York, 1995; pp 433–435.Google Scholar
  66. World Health Organization. Guidelines for the Use of Androgens in Men. Geneva: WHO; 1992.Google Scholar
  67. Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 1996; 65:626–636.Google Scholar
  68. Zhang GY, Gu YO, Wang XH, Cui YG, Bremner WJ. Pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl, 1998; 19:761–768.PubMedGoogle Scholar
  69. Zhi L, Tegley CM, Kallel EA, Marschke KB, Mais DE, Gottardis MM, Jones TK. 5-Aryl-1,2-dihydrochromeno [3-4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem 1998; 41:291–302.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • C. Wang
    • 1
  • R. S. Swerdloff
    • 1
  1. 1.Harbor-UCLA Medical CenterTorrance

Personalised recommendations